When the HF patients were treated withcontinuous-flow LV assist device (LVAD) for 8±1.7 months, improvement inhemodynamic parameters (LV end diastolic volume decreased from 294.9 mL to 237.8mL, LV diastolic diameter from 7.6 cm to 6.8 cm, and LV end systolic volume from244.8 mL to 183.4 mL, reflected in an increase in LVEF from 18.2 to29.6%, p<0.05 for all) was accompanied by a marked decrease in mRNAlevels of CXCR5 as well as biglycan and fibromodulin, although the decrease infibromodulin did not reach statistical significance (Fig. 8). This evidence concerns the gene CXCR5 and hydrops fetalis.